Researchers and clinicians face ethical and policy-based challenges in disclosing, preventing and treating psychosis. Which diagnostic labels should be considered to motivate more effective public and professional dialogue about psychosis risk?
AMA J Ethics. 2016;18(6):624-632. doi:
10.1001/journalofethics.2016.18.6.msoc1-1606.
Daphne C. Ferrer, MD and Peter M. Yellowlees, MBBS, MD
Telepsychiatry extends access to psychiatric treatment to those who might not otherwise get it, but licensure problems and the risk of boundary violations between patients and physicians need to be worked out.
The FDA's decision to put a black-box warning on antidepressant labels may be misleading because it implies that antidepressants have definitely been found to increase suicidality in adolescents, when in fact there is merely a lack of clear evidence about their safety.